AAD Licensed Content

The talk reviewed recent medical dermatology advances with emphasis on new oral and immune-modulating therapies. For chronic spontaneous urticaria, rembrutinib, an oral BTK inhibitor, was highlighted as a…

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Recent Advances and Emerging Therapies in Medical Dermatology

Description

The talk reviewed recent medical dermatology advances with emphasis on new oral and immune-modulating therapies. For chronic spontaneous urticaria, rembrutinib, an oral BTK inhibitor, was highlighted as a potentially practice-changing option because it acts quickly, works in both IgE- and IgG-mediated disease, requires no lab monitoring, and improves itch, hives, sleep, and quality of life; the main safety concern discussed was mild mucocutaneous bleeding rather than major thrombotic or malignant risk. In psoriasis, the speaker described icodacitinib, an oral IL-23 receptor antagonist, as the first oral option approaching biologic-level efficacy, though likely somewhat less effective than injectable biologics and dependent on empty-stomach dosing. A separate high-dose IL-23 “knockout” study suggested that short bursts of intense therapy may deplete tissue-resident memory T cells and induce prolonged remission for some patients. The lecture also covered OX40-pathway drugs, which may broadly reset inflammatory disease but raised safety concerns after cases of Kaposi sarcoma, limiting enthusiasm. By contrast, the IL-2 agonist respeg (designed to expand regulatory T cells) showed encouraging, gradually deepening responses in atopic dermatitis with frequent but usually tolerable injection-site reactions. In alopecia areata, the newest data for apacitinib suggested strong early efficacy and potentially best-in-class results, while long-term follow-up for baricitinib and ritlecitinib remained reassuring for sustained benefit and safety.

View more

Conclusions

  • The presentation concludes that remibrutinib offers a fast-acting oral BTK-inhibitor option for chronic spontaneous urticaria with strong symptom improvement and a generally manageable safety profile, though mucocutaneous bleeding should be discussed.
  • It concludes that icotrokinra provides the first oral IL-23 receptor antagonist for psoriasis with efficacy that is better than deucravacitinib and comparable to ustekinumab, but still below the strongest injectable biologics.
  • It concludes that the KNOCKOUT study suggests high-dose intermittent IL-23 blockade may deplete tissue-resident memory T cells and induce prolonged psoriasis remission after only a few doses.
  • It concludes that the anti-OX40 strategy is biologically promising but currently undermined by Kaposi sarcoma safety concerns, leading to rocatinlimab withdrawal and greater caution for the class.
  • It concludes that rezpegaldesleukin represents a novel immune-tolerance approach in atopic dermatitis, with responses that deepen over time and may allow less frequent maintenance dosing.
  • It concludes that upadacitinib appears highly effective for alopecia areata, producing deep hair-regrowth responses with substantial rates of SALT 10 and SALT 0 improvement.
  • It concludes that baricitinib has durable five-year efficacy and reassuring long-term safety in alopecia areata, with no major new safety signals emerging.
  • It concludes that ritlecitinib also shows progressive long-term benefit in alopecia areata, although its response appears slower and less deep than upadacitinib.
  • Overall, the presentation concludes that dermatology is moving toward more oral, mechanism-based therapies that can produce deeper and sometimes more durable disease control than older approaches.
  • It concludes that future treatment selection will increasingly depend on shared decision-making that balances efficacy, route of administration, durability, and class-specific safety concerns.
  • Darragh A et al. Adapted with permission. Creative Commons license: https://creativecommons.org/licenses/by/4.0/.
  • Giménez-Arnau et al. REMIX-1 and REMIX-2 Phase 3 trials. Creative Commons link.
  • Lancet. 2025. DOI: 10.1016/S0140-6736(25)01576-4.#10.1016/S0140-6736(25)01576-4
  • Lancet. 2018. DOI reference cited on comparison slides.
  • Nature Communications. 2025/2026. Phase 2 KNOCKOUT Study.
  • Springer URL (OX-40 pathway slide).
  • J Exp Med. 2013. PMID cited on rocatinlimab/Kaposi sarcoma slide.
  • Nektar Therapeutics. REZOLVE-AD Phase 2b. NCT06136741.
  • AbbVie. UP-AA Phase 3 Studies 1 & 2. 2025.
  • Lilly. Baricitinib Integrated Safety Analysis. BRAVE Program Long-Term Extension.
  • Pfizer. ALLEGRO-LT 3-Year Data. 2025/2026.